Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Der Stellenwert neuer Therapiekonzepte und hämatopoetischer Wachstumsfaktoren bei der Behandlung urologischer Tumoren

  • 7 Accesses

  • 1 Citations

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Weißbach L (1994) Consensus Statement — Urologen-Workshop Lissabon 1992. Urologe [B] 34: 127–128

  2. 2.

    Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 315: 164–170

  3. 3.

    Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29 A: 319–324

  4. 4.

    Gebbia V, Testa A, Valenza R et al (1993) A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma. J Chemother 5: 186–190

  5. 5.

    Testa A, Gebbia V, Carreca I et al (1993) Treatment of recurrent and/or metastatic transitional cell urinary bladder carcinoma with methotrexate, cisplatin, and high-dose epidoxorubicin with or without granulocyte colony-stimulating factor. Cancer Res, Ther and Contr 3: 303–307

  6. 6.

    Fossa S, Kaye SB, Mead GM et al (1995) An MRC/EORTC randomised trial in poor prognosis metastatic teratoma, comparing treatment with/without filgrastim (G-CSF). Proceedings of ASCO 14: Abstract 656

  7. 7.

    Beyer J, Schwella N, Zingsem J et al (1995) Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 13: 1328–1335

  8. 8.

    Weh H, de Wit M, Zornig C, Hossfeld DK (1996) Treatment of adult metastatic soft-tissue sarcoma with Doxorubicin/Ifosfamide: better hematologic tolerance by G-CSF? Onkologie 19: 159–162

  9. 9.

    Mäher D, Lieschke G, Green M et al (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. Ann Int Med 121: 492–501

  10. 10.

    Mitchell P, Morland B, Dick G et al (1995) Clinical benefits and cost savings of interventional G-CSF therapy in patients with febrile neutropenia following chemotherapy. Blood 86: [Suppl 1] Abstract 1989

  11. 11.

    ASCO Panel (1994) American Society of Clinical Oncology Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 12: 2471–2508

  12. 12.

    Bokemeyer C, Kuczyk MA, Köhne H et al (1996) Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 72: 1–9

  13. 13.

    Williams S, Birch R, Einhorn L et al (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435–1440

  14. 14.

    Einhorn L (1995) In: Schnorr D, Loening S, Weißbach L (Hrsg) Hodentumoren. Blackwell Wissenschafts-Verlag Berlin

Download references

Author information

Correspondence to Prof. Dr. L. Weißbach.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Weißbach, L., Schlimok, G., Schmoll, H.-. et al. Der Stellenwert neuer Therapiekonzepte und hämatopoetischer Wachstumsfaktoren bei der Behandlung urologischer Tumoren. Der Urologe B 36, 256–259 (1996). https://doi.org/10.1007/s001310050023

Download citation